MedTrace Logo

Comparison of MI Paste Plus and Resin Infiltration in White Spot Lesions Following Orthodontic Treatment

NCT05733676 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-07-04

No results posted yet for this study

Summary

Dental cavities are among the most frequent diseases that affect teeth, particularly in patients who are treated with braces due to the difficulty in maintaining good oral hygiene in the presence of the mouth appliances. The white spot lesion (WSL) is the first clinical sign of cavities that presents itself as a milky-white opacity when located on the front face of the tooth. The aim to manage these early lesions focuses on promoting natural remineralization and preventing further demineralization. Various materials have been introduced for management of WSLs including MI paste and MI paste combined with fluoride (MI paste plus). Recently, a new material called resin infiltration has been found to treat these lesions with high esthetic results and great performance. According to the few numbers of in-vivo studies investigating the effectiveness of remineralization products, the aim of the current study is to clinically compare the outcome of the resin-infiltration and etching + MI paste plus to stop and improve the appearance of the WSL on front teeth in patients after treatment with braces.

Conditions

  • White Spot Lesions
  • Orthodontic Appliance Complication
  • Caries Arrested
  • Smooth Surface Caries

Interventions

DEVICE

Resin infiltration

Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.

DEVICE

Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride

Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Ida M Kornerup, DMD, MEd · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2026-03-01
Completion
2026-10-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733676 on ClinicalTrials.gov